泽璟制药：ZG006和ZG005将在2025年欧洲肿瘤内科学会年会发布临床数据

Core Viewpoint - Zai Lab's new drugs Alveltamig (ZG006) and Nilvanstomig (ZG005) will present clinical research data at the European Society for Medical Oncology (ESMO) annual meeting from October 17 to 21, 2025, highlighting their innovative approaches in targeting DLL3 [1] Group 1: Drug Development - ZG006 is the world's first tri-specific antibody targeting DLL3 (DLL3×DLL3×CD3), representing a first-in-class molecular form with the potential to become a best-in-class molecule [1] - ZG005 is one of the first drugs to enter clinical research targeting the same mechanism, with no similar mechanism drugs approved globally [1]